Browsing by Author "Gupta, Nidhi"

Filter results by typing the first few letters
Now showing 1 - 2 of 2
  • No Thumbnail Available
    Item
    1,3-Oxazine as a Promising Scaffold for the Development of Biologically Active Lead Molecules
    (John Wiley and Sons Inc, 2023-10-16T00:00:00) Gupta, Nidhi; Saini, Vipin; Basavarajaiah, S.M.; Dar, Mohammad Ovais; Das, Rina; Dahiya, Randhir Singh
    Heterocyclic compounds form an important part of wide range of biologically active molecules. The heteroatom provides them specificity for various receptors. 1,3-oxazine has been considered as a privileged scaffold in many medicinal chemistry applications. Compounds having 1,3-oxazine moiety exhibit broad range of biological applications such as anticancer, antimicrobial, anti-inflammatory, antiplatelet, antitubercular and alpha-glucosidase inhibition activities. In this review, we consolidate the recent developments in the synthesis and biological activities of 1,3-oxazine containing compounds. Also, the structure activity relationship (SAR) studies of different derivatives exhibiting several biological activities are summarized. Database such as Science direct, Pubmed and Google scholar were searched using keywords �1,3-Oxazine�, �synthesis�, �derivatives�, and �biological activities�. The review would provide a lead for the development of competent candidates with 1,3-oxazine moiety having broad range of applications in the treatment of several human disorders. � 2023 Wiley-VCH GmbH.
  • No Thumbnail Available
    Item
    Multi-pathogen based chimeric vaccine to fight against COVID-19 and concomitant coinfections
    (Springer Science and Business Media B.V., 2023-05-06T00:00:00) Ojha, Rupal; Singh, Satyendra; Gupta, Nidhi; Kumar, Ketan; Padhi, Aditya K.; Prajapati, Vijay Kumar
    Background: COVID-19 has proved to be a fatal disease of the year 2020, due to which thousands of people globally have lost their lives, and still, the infection cases are at a high rate. Experimental studies suggested that SARS-CoV-2 interacts with various microorganisms, and this coinfection is accountable for the augmentation of infection severity. Methods and results: In this study, we have designed a multi-pathogen vaccine by involving the immunogenic proteins from S. pneumonia, H. influenza, and M. tuberculosis, as they are dominantly associated with SARS-CoV-2. A total of 8 antigenic protein sequences were selected to predict B-cell, HTL, and CTL epitopes restricted to the most prevalent HLA alleles. The selected epitopes were antigenic, non-allergenic, and non-toxic and were linked with adjuvant and linkers to make the vaccine protein more immunogenic, stable, and flexible. The tertiary structure, Ramachandran plot, and discontinuous B-cell epitopes were predicted. Docking and MD simulation study has shown efficient binding of the chimeric vaccine with the TLR4 receptor. Conclusion: The in silico immune simulation analysis has shown a high level of cytokines and IgG after a three-dose injection. Hence, this strategy could be a better way to decrease the disease's severity and could be used as a weapon to prevent this pandemic. � 2023, The Author(s), under exclusive licence to Springer Nature B.V.